Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
The interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 blockade therapy, which prevents the receptors and ligands fr...
Main Authors: | Jiqiao Yang, Xiujing He, Qing Lv, Jing Jing, Hubing Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00726/full |
Similar Items
-
Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events
by: Tongji XIE, et al.
Published: (2020-07-01) -
GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01) -
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017-01-01) -
Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer
by: Yan SHI, et al.
Published: (2017-11-01) -
Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer
by: Witold Zgodzinski, et al.
Published: (2018-04-01)